人源化 PD-1 敲入小鼠揭示纳武单抗对神经胶质瘤肿瘤进展的抑制作用。
Humanized PD-1 Knock-in Mice Reveal Nivolumab's Inhibitory Effects on Glioblastoma Tumor Progression .
机构信息
Ph.D. Program of Electrical and Communications Engineering, Feng Chia University, Taichung, Taiwan, R.O.C.
Department of Medical Imaging, Show Chwan Memorial Hospital, Changhua, Taiwan, R.O.C.
出版信息
In Vivo. 2023 Sep-Oct;37(5):1991-2000. doi: 10.21873/invivo.13296.
BACKGROUND/AIM: Immunotherapy has been considered a promising approach for brain tumor treatment since the discovery of the brain lymphatic system. Glioblastoma (GBM), the most aggressive type of brain tumor, is associated with poor prognosis and a lack of effective treatment options.
MATERIALS AND METHODS
To test the efficacy of human anti-PD-1, we used a humanized PD-1 knock-in mouse to establish an orthotopic GBM-bearing model.
RESULTS
Nivolumab, a human anti-PD-1, effectively inhibited tumor growth, increased the survival rate of mice, enhanced the accumulation and function of cytotoxic T cells, reduced the accumulation and function of immunosuppressive cells and their related factors, and did not induce tissue damage or biochemical changes. The treatment also induced the accumulation and activation of CD8 cytotoxic T cells, while reducing the accumulation and activation of myeloid-derived suppressor cells, regulatory T cells, and tumor-associated macrophages in the immune microenvironment.
CONCLUSION
Nivolumab has the potential to be a treatment for GBM.
背景/目的：自脑淋巴系统被发现以来，免疫疗法已被认为是治疗脑肿瘤的一种很有前途的方法。神经胶质瘤（GBM）是最具侵袭性的脑肿瘤之一，预后不良，缺乏有效治疗方法。
材料和方法
为了测试人源抗 PD-1 的疗效，我们使用人源化 PD-1 敲入小鼠建立了原位 GBM 荷瘤模型。
结果
纳武单抗，一种人源抗 PD-1，有效抑制肿瘤生长，提高了小鼠的存活率，增强了细胞毒性 T 细胞的积累和功能，减少了免疫抑制细胞及其相关因子的积累和功能，并且不会引起组织损伤或生化变化。该治疗还诱导了 CD8 细胞毒性 T 细胞的积累和激活，同时减少了免疫微环境中髓系来源的抑制细胞、调节性 T 细胞和肿瘤相关巨噬细胞的积累和激活。
结论
纳武单抗有可能成为 GBM 的一种治疗方法。
Zotero 插件